Literature DB >> 12162503

Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts.

K Suzuki1, B Zhu, S R Rittling, D T Denhardt, H A Goldberg, C A G McCulloch, J Sodek.   

Abstract

Although osteopontin (OPN) is recognized generally as a secreted protein, an intracellular form of osteopontin (iOPN), associated with the CD44 complex, has been identified in migrating fibroblastic cells. Because both OPN and CD44 are expressed at high levels in osteoclasts, we have used double immunofluorescence analysis and confocal microscopy to determine whether colocalization of these proteins has functional significance in the formation and activity of osteoclasts. Analysis of rat bone marrow-derived osteoclasts revealed strong surface staining for CD44 and beta1- and beta3-integrins, whereas little or no staining for OPN or bone sialoprotein (BSP) was observed in nonpermeabilized cells. In permeabilized perfusion osteoclasts and multinucleated osteoclasts, staining for OPN and CD44 was prominent in cell processes, including filopodia and pseudopodia. Confocal microscopy revealed a high degree of colocalization of OPN with CD44 in motile osteoclasts. In cells treated with cycloheximide (CHX), perinuclear staining for OPN and BSP was lost, but iOPN staining was retained within cell processes. In osteoclasts generated from the OPN-null and CD44-null mice, cell spreading and protrusion of pseudopodia were reduced and cell fusion was impaired. Moreover, osteoclast motility and resorptive activity were significantly compromised. Although the area resorbed by OPN-null osteoclasts could be rescued partially by exogenous OPN, the resorption depth was not affected. These studies have identified an intracellular form of OPN, colocalizing with CD44 in cell processes, that appears to function in the formation and activity of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162503     DOI: 10.1359/jbmr.2002.17.8.1486

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  53 in total

1.  MT1-MMP: A novel component of the macrophage cell fusion machinery.

Authors:  Pilar Gonzalo; Alicia G Arroyo
Journal:  Commun Integr Biol       Date:  2010-05

Review 2.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

3.  Modulation of unloading-induced bone loss in mice with altered ERK signaling.

Authors:  Jeyantt S Sankaran; Bing Li; Leah Rae Donahue; Stefan Judex
Journal:  Mamm Genome       Date:  2015-11-06       Impact factor: 2.957

4.  Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen.

Authors:  Ted S Gross; Katy A King; Natalia A Rabaia; Pranali Pathare; Sundar Srinivasan
Journal:  J Bone Miner Res       Date:  2004-10-11       Impact factor: 6.741

5.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 6.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

7.  Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells.

Authors:  Pongsanat Pongcharoen; Artit Jinawath; Rutaiwan Tohtong
Journal:  Clin Exp Metastasis       Date:  2011-08-11       Impact factor: 5.150

8.  The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions.

Authors:  Cristina Vincent; Masakazu Kogawa; David M Findlay; Gerald J Atkins
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

9.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

10.  The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.

Authors:  Nadia Rucci; Anna Rufo; Marina Alamanou; Mattia Capulli; Andrea Del Fattore; Emma Ahrman; Daria Capece; Valeria Iansante; Francesca Zazzeroni; Edoardo Alesse; Dick Heinegård; Anna Teti
Journal:  J Cell Biol       Date:  2009-11-30       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.